VNA
BIB icon

Valley National Advisers’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Valley National Advisers’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-25
Closed -$2K – 668
2017
Q3 		$2K Buy
+25
New +$1.42K ﹤0.01% 536

Other funds holding BIB

OPPM
Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
CIC
Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return
PCA
Private Capital Advisors Darien, Connecticut $872M AUM 26.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
BA
BKS Advisors Southfield, Michigan $249M AUM 14.37% 1-Year Est. Return
BRC
Bell Rock Capital Rehoboth Beach, Delaware $81M AUM 9.85% 1-Year Est. Return

Valley National Advisers's BIB Position: Q4 2017 in Review

Valley National Advisers sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q4 2017, closing a stake of 25 shares — an estimated $2K sold.

Valley National Advisers first reported a position in BIB in Q3 2017 and held it in 1 quarter. The position peaked at $2K in Q3 2017. 40 funds tracked by Wall St. Rank hold BIB as of Q4 2017.

  • Valley National Advisers reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q4 2017 after selling out during the quarter.
  • Valley National Advisers sold 25 ProShares Ultra NASDAQ Biotechnology shares in Q4 2017, an estimated $2K.
  • Valley National Advisers first reported a position in ProShares Ultra NASDAQ Biotechnology in Q3 2017 and held it in 1 quarter.
  • Valley National Advisers's ProShares Ultra NASDAQ Biotechnology position peaked at $2K in Q3 2017.
  • 40 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q4 2017.

Based on Valley National Advisers's 13F filing for Q4 2017, filed 13 Feb 2018.